Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Obsessive-Compulsive Disorder

Obsessive-Compulsive Disorder

Obsessive-compulsive disorder (OCD) is a mental health condition characterized by recurrent obsessions, compulsions, or both, which consume significant time and interfere with daily functioning. Obsessions involve persistent, intrusive, and unwanted thoughts, images, or urges that evoke anxiety. Common examples include irrational fears of contamination or harm. Compulsions are repetitive behaviors or mental acts performed to reduce the anxiety caused by obsessions. For instance, individuals...

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...

Psychosis and Antipsychotic Drugs: Overview

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...

Personality Disorders: Dependent and Obsessive-Compulsive

Personality Disorders: Dependent and Obsessive-Compulsive

Dependent personality disorder and obsessive-compulsive personality disorder are two separate psychological conditions that influence behavior, relationships, and overall life functioning. Though both involve maladaptive behaviors, their core characteristics and motivations differ significantly.
Dependent Personality Disorder
Dependent personality disorder is characterized by an excessive reliance on others to manage various aspects of life. Individuals with this disorder often struggle with...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Changes in biodiversity drive trypanosome infections of wildlife in Panama.

One health (Amsterdam, Netherlands)·2025

Same author

Enhancing mental health care: a problem, resources and goals oriented multidimensional framework (PRoGO).

European archives of psychiatry and clinical neuroscience·2025

Same author

Why Is Clozapine Uniquely Effective in Treatment-Resistant Schizophrenia? A Review and Proposal.

Biological psychiatry·2025

Same author

Efficacy and tolerability of pharmacological interventions for schizophrenia non-responsive to prior treatment: a systematic review and network meta-analysis.

EClinicalMedicine·2025

Same author

Effectiveness of psychotherapy: Synthesis of a "meta-analytic research domain" across world regions and 12 mental health problems.

Psychological bulletin·2025

Same author

Sexual dysfunction and other prolactin-related side effects of antipsychotic drugs in schizophrenia: Protocol for a systematic review with single-arm, pairwise, and network meta-analyses of randomized controlled trials and non-randomized studies.

F1000Research·2025

Search research articles

Related Experiment Video

Updated: Jun 6, 2026

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder

Published on: January 9, 2015

Second-generation antipsychotics for obsessive compulsive disorder.

Katja Komossa¹, Anna M Depping, Magdalena Meyer

¹Klinik und Poliklinik für Psychiatrie und Psychotherapie, Technische Universität München Klinikum rechts der Isar, Moehlstrasse 26, München, Germany, 81675.

The Cochrane Database of Systematic Reviews

|December 15, 2010

Summary

Second-generation antipsychotics (SGAs) show potential for treating obsessive-compulsive disorder (OCD) when added to antidepressants. Risperidone and quetiapine demonstrated efficacy, but tolerability and data limitations require careful consideration.

More Related Videos

Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder

Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder

Published on: November 25, 2025

Exploring the Neural Correlates of Cognitive Reappraisal in Obsessive-Compulsive Disorder Using Task-based Functional Magnetic Resonance Imaging

Exploring the Neural Correlates of Cognitive Reappraisal in Obsessive-Compulsive Disorder Using Task-based Functional Magnetic Resonance Imaging

Published on: March 14, 2025

Related Experiment Videos

Last Updated: Jun 6, 2026

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder

Published on: January 9, 2015

Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder

Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder

Published on: November 25, 2025

Exploring the Neural Correlates of Cognitive Reappraisal in Obsessive-Compulsive Disorder Using Task-based Functional Magnetic Resonance Imaging

Exploring the Neural Correlates of Cognitive Reappraisal in Obsessive-Compulsive Disorder Using Task-based Functional Magnetic Resonance Imaging

Published on: March 14, 2025

Area of Science:

Psychiatry
Pharmacology
Clinical Trials

Background:

Obsessive-compulsive disorder (OCD) affects 2-3.5% of the population.
40-60% of individuals show inadequate response to first-line SSRI treatments.
Efficacy and adverse effects of second-generation antipsychotics (SGAs) in OCD are not well-established.

Purpose of the Study:

To evaluate the efficacy and adverse effects of SGAs as monotherapy or add-on treatment for OCD.
Comparison against placebo or other pharmaceutical treatments.

Main Methods:

Systematic review of double-blind randomized controlled trials (RCTs).
Searched Cochrane registers, ClinicalTrials.gov, and contacted pharmaceutical companies.
Included 11 RCTs with 396 participants comparing oral SGAs in adults with primary OCD.

Main Results:

Olanzapine showed no significant difference in efficacy but increased weight gain.
Quetiapine added to antidepressants improved Yale-Brown Obsessive Compulsive Scale scores and reduced anxiety/depression.
Risperidone added to antidepressants was more efficacious in reducing OCD symptoms, anxiety, and depression.

Conclusions:

Limited data exist for olanzapine in OCD treatment.
Quetiapine and risperidone show potential as add-on treatments to antidepressants for OCD.
Potential benefits must be weighed against tolerability issues and limited available data.